Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 13/20 | 0.52 |
| ▸ | KDR | P35968 | 7/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | JAK3 | P52333 | 4/20 | 0.45 |
| ▸ | TEK | Q02763 | 3/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501609 | 0.89 | LCK (0.55) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5504546 | 0.88 | LCK (0.49) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5501869 | 0.87 | LCK (0.52) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5498641 | 0.87 | LCK (0.53) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5498568 | 0.83 | LCK (0.49) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5497124 | 0.82 | LCK (0.63) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5501916 | 0.81 | LCK (0.46) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5491403 | 0.81 | LCK (0.60) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5497764 | 0.80 | LCK (0.49) | LCKKDRMAPK14JAK3TEK | |
| SCHEMBL5501412 | 0.80 | LCK (0.49) | LCKKDRMAPK14JAK3TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LCK 106/4885KDR 1044/4885MAPK14 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.